Speaker Profile

M.D., Ph.D., Professor, University of Washington

The focus of Dr. Rabinovitch’s research is on the use of mouse models to examine the effects of modulating mitochondrial function on lifespan and healthspan. Transgenic mice that express catalase in mitochondria, as well as the tetrapeptide SS-31 (elamipretide) have been found to be protected against multiple health challenges, including cardiac aging and sarcopenia. His work tests the hypothesis that acute enhancement of mitochondrial function is followed by persistent structural, proteomic and metabolic remodeling that improves aged physiological performance. Studies of proteomic abundance, turnover and post-translational modification have been invaluable tools in this work. Dr. Rabinovitch is a Fellow of the AAAS, past recipient of the Denham Harmon Research Award from the American Aging Association, an Ellison Medical Foundation Senior Scholar in Aging grant award, and a Breakthroughs in Gerontology grant award from the American Federation for Aging Research.

Interventions To Enhance Aging Muscle Mitochondrial Function
Treatment with the mitochondrial targeted peptide SS-31 (elamipretide) or late-life viral expression of mitochondrial-targeted catalase (mCAT) can substantially reverse cardiac dysfunction and reduced endurance of old mice. These results implicate mitochondrial energetics and redox signaling as therapeutic targets for muscle aging.

 Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2022 Wellness & Aging Showcase will provide a 15-minute time slot for selected companies in Wellness and Aging to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from selected companies that build innovative solutions and harness the power of digital health, genomics, and data science with the goal to proactively prevent disease, maintain optimal health, and slow down aging.